Some multiple sclerosis treatments come as injections, which are given either under your skin or into a muscle. The shot might make your skin sore, red, itchy, or dimply. Beta interferons are ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...

While almost 3 million people worldwide live with multiple sclerosis (MS), many people may not understand the complexity of this unpredictable condition. MS Awareness Month aims to change this and ...

High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

The treatment, called Ocrevus Zunovo, was approved as a biannual, approximately 10-minute, under-the-skin injection for patients with relapsing multiple sclerosis and primary progressive multiple ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...